Brief: Ultimovacs Q2 Operating Expenses at NOK 50.6 Million
22/08/2023 07:03
Aug 22 (Reuters) - Ultimovacs Q2 operating expenses NOK 50.6 million
Recent news on Zelluna ASA
See all newsNorway's Zelluna ASA reports Q2 loss
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant